We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editor's Correspondence |

Cardiovascular Safety of Low-Dose Rosiglitazone

Nasser Mikhail, MD, MSc
Arch Intern Med. 2008;168(1):109. doi:10.1001/archinternmed.2007.17.
Text Size: A A A
Published online


In the trial by Hollander et al,1 the excess rates of cardiovascular (CV) events with rosiglitazone use (2.4% in the 2-mg/d group and 1.4% in the 4-mg/d group vs 0.9% in the placebo group) are of concern because of several reasons. First, these events occurred with rosiglitazone doses as low as 2 mg/d and after short-time exposure to the drug (within 24 weeks). Second, they were in agreement with the overall results of a meta-analysis2 of 42 trials showing that rosiglitazone use was associated with a significant risk of myocardial infarction (odds ratio, 1.43; 95% confidence interval, 1.03-1.98 [P = .03]). The meta-analysis2 included the trial by Hollander et al1 before its publication and peer review, when it was reported in a summary fashion on the Web site of the drug manufacturer. Although the interim data of the randomized RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes) trial did not suggest a significant increase in the incidence of myocardial infarction or deaths from CV causes with rosiglitazone use, the frequency of congestive heart failure more than doubled in the rosiglitazone group compared with the control group (hazard ratio, 2.24; 95% confidence interval, 1.27-3.97 [P = .006]).3 Third, the authors' description that the excess rates of CV events are only “slight” and may be attributed to the high frequency of CV risk factors at baseline among patients randomized to rosiglitazone is by no means reassuring. Indeed, the impact of this “slight” increase in CV events can be substantial because millions of patients are using rosiglitazone worldwide. Moreover, the early occurrence of CV events argues against the unfavorable CV risk profile in the rosiglitazone groups at the study entry being a major contributing factor. Fourth, it is well known that rosiglitazone in maximum doses (8 mg/d) adversely affects plasma lipids by increasing levels of low-density lipoproteins and triglycerides by up to 23% and 15%, respectively.4 It would be interesting to know the changes in plasma lipids in the study by Hollander et al1 with low rosiglitazone doses.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles